Loading...
  • carcinomatosis
  • The development of peritoneal carcinomatosis involves well-defined steps including cell shedding and transport, adhesion to the mesothelial layer, invasion of and proliferation into the submesothelial stroma, and potential access to the systemic circulation. (ugent.be)
  • dialysate
  • HD implies the existence of a vascular access, such as an arteriovenous fistula/graft or a venous catheter, whereas PD implies a long-term peritoneal catheter and the constant inflow of peritoneal dialysate. (bioportfolio.com)
  • Correlation analyses revealed that PrCl was positively correlated with diabetes, pulse pressure, C-reactive protein CRP level, dialysate-plasma creatinine ratio D-P cr at 4 h, and peritoneal Kt-V urea. (duhnnae.com)
  • Chronic Kidney
  • Chronic kidney disease (CKD) is associated with an imbalanced human microbiome due not only to CKD-associated factors such as uremia, increased inflammation and immunosuppression, but also to pharmacological therapies and dietary restrictions. (bioportfolio.com)
  • Pharmacokinetics and drug interactions of medications used to treat hepatitis C virus infection in the setting of chronic kidney disease and kidney transplantation. (bioportfolio.com)
  • To evaluate the safety, pharmacokinetics, and pharmacodynamics in nondialysis (ND) and hemodialysis (HD) subjects with Chronic Kidney Disease (CKD) who receive a single administration of T. (bioportfolio.com)
  • metastatic
  • In this Review, we summarise the molecular mechanisms and potential preventive measures associated with each step of the peritoneal metastatic cascade. (ugent.be)
  • mortality
  • In conclusion, postoperative ARF was associated with increased mortality in children operated for congenital heart disease. (nih.gov)
  • catheter
  • Peritoneal access should be implanted surgically by surgeon (laparascopic technique if possible) or the bedside-placed acute catheter. (bmj.com)
  • During peritoneal dialysis, a small flexible tube, known as a catheter, is attached to an incision in the abdomen. (bhf.org.uk)
  • treatment
  • We report the 1stcase of severe, symptomatic hypocalcemia after denosumab (RANKL inhibitor) treatment in a peritoneal dialysis patient with secondary hyperparathyroidism and osteoporosis. (sciencedomain.org)
  • If this and larger trials prove successful, peritoneal dialysis could become a treatment option for people with heart failure and kidney disease in the future. (bhf.org.uk)
  • The accurate diagnosis can be a powerful guarantee for the kidney disease treatment While the accurate dialysis needs the support from the advanced medical inspection equipments which achieve world-class level. (kidney-support.org)
  • Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. (clinicaltrials.gov)
  • It has been hypothesized that the combination of bevacizumab with CRLX101 might have unique clinical activity in combination in the treatment of this disease due to the simultaneous inhibition of distinct steps along the HIF → (CAIX) → VEGF → VEGFR2 pathway. (clinicaltrials.gov)
  • progression-free sur
  • Progression-free survival was defined as the time interval from study entry until disease progression or death due to any cause, whichever came first. (clinicaltrials.gov)
  • In the absence disease progression or death, progression-free survival was censored at the last date the participant was known to be alive. (clinicaltrials.gov)
  • criteria
  • Participants were treated for at least one 8-week cycle, with additional cycles as long as they had stable or responding disease (per RECIST criteria) and wished to remain on study. (clinicaltrials.gov)
  • Clinical benefit rate was defined as the percentage of participants with complete response, partial response or stable disease according to RECIST criteria. (clinicaltrials.gov)
  • Stable Disease is any condition not meeting the above criteria. (clinicaltrials.gov)
  • kidney disease
  • It is such a place where you can share your experience, see the international news about kidney disease and find the answers to the questions bothering. (kidney-support.org)
  • So as a kidney disease patient you should cooperate with your doctor to solve this problem. (kidney-support.org)
  • If you need any help in treating constipation in kidney disease or have other questions about dialysis, you are welcome to contact our doctor on WhatsApp/Viber, we are here waiting to help you. (kidney-support.org)
  • protein
  • Although a number of studies have been published on peritoneal protein clearance PrCl and its association with patient outcomes, the results have been inconsistent. (duhnnae.com)
  • absence
  • Consolidation therapy begins within 3-14 days after second-look surgery and continues for 24 weeks in the absence of disease progression. (clinicaltrials.gov)
  • symptoms
  • Indeterminate is defined as having no repeat tumor assessments following initiation of study therapy for reasons unrelated to symptoms or signs of disease. (clinicaltrials.gov)
  • study
  • The present single-center cohort study was based on a clinical intensive care unit database containing data on 1128 consecutive children undergoing their first operation for congenital heart disease between 1993 and 2002 at Aarhus University Hospital, Skejby, Denmark. (nih.gov)
  • Participants had a final follow-up visit within 4 weeks following the last dose of iniparib, after which time they were contacted by study staff every 3 months for the first year and every 6 months thereafter to assess disease status and survival. (clinicaltrials.gov)
  • Disease Progression is at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD or the appearance of new lesions within 8 weeks of study entry. (clinicaltrials.gov)
  • Baseline clinical, laboratory and disease severity parameters will be evaluated for each study patient. (clinicaltrials.gov)